Decoding health through molecular insight.

Aitiologic is a precision medicine startup providing multi-modal liquid biopsy solutions for early disease detection and targeted therapy.

Platform

Technology foundation and first applications.

We are building the first multi-modal liquid biopsy platform to decode genomic, epigenomic, and fragmentomic cfDNA signals at single-molecule resolution from a simple blood draw.

Technology

Aitios® Platform

Foundational multi-modal liquid biopsy platform for tissue-resolved cfDNA signal interpretation.

Explore

Application

Aitios® NIPPT

First-trimester Non-Invasive Prenatal and Preeclampsia Testing for early risk stratification.

Explore

Updates

Latest news and events.

AJOG Global Reports

June 2026

First-Trimester Multi-modal cfDNA Analysis for Prediction of Preterm and Term Preeclampsia

First-trimester multi-modal, tissue-resolved cfDNA analysis enables early risk stratification across the full clinical spectrum of preeclampsia from a single routine blood sample.

Read in AJOG Global Reports

White Paper

May 2026

Screening is the adherence prevention

Aspirin works. Yet U.S. preeclampsia rates keep rising. The failure is not pharmacological — it is a failure of risk identification that asks 9 in 10 pregnant women to take a drug they will rationally decline. A look at the evidence for why first-trimester multi-modal screening, not broader checklists, will finally close the preeclampsia prevention gap.

Read white paper

Upcoming event

J.P. Morgan - The Munich LifeScience Forum 2026

Sep 16, 2026 | Munich, Germany

Meet us at J.P. Morgan's Munich LifeScience Forum in Munich for conversations across biotechnology, life science company building, investment, and translational innovation.

Meet us

Sep 15, 2026

Aitiologic Raises €6.4 Million in Oversubscribed Seed Financing to Advance Tissue-Resolved Liquid Biopsy Platform and Preeclampsia Lead Program

The financing, co-led by Heal Capital and Ananda Impact Ventures, will advance the Aitios® Platform and its lead program for first-trimester preeclampsia risk assessment.

Read on GlobeNewswire

Dec 6, 2025

Aitiologic Takes on Preeclampsia: Preparing for Large-Scale Validation after Presentation of Feasibility Study at FMF Conference in London

Aitiologic's Chief Medical Officer, Dr. Rebecca Ertl, presented the first feasibility results of the Aitios® platform for tissue-specific liquid biopsy to over 1,500 clinicians and researchers.

Open article

Network & Development Partners